Targeted protein modification as a paradigm shift in drug discovery

• Published in: European journal of medicinal chemistry Vol. 260; p. 115765
• Main Authors: Amirian, Roshanak, Azadi Badrbani, Mehdi, Izadi, Zhila, Samadian, Hadi, Bahrami, Gholamreza, Sarvari, Sajad, Abdolmaleki, Sara, Nabavi, Seyed Mohammad, Derakhshankhah, Hossein, Jaymand, Mehdi
• Format: Journal Article
• Language: English
• Published: Elsevier Masson SAS 15-11-2023
• Subjects: AbTAC; ATTEC; AUTAC; LYTAC; PROTAC; LYTAC; AUTAC; ATTEC; AbTAC; PROTAC
• ISSN: 0223-5234; 1768-3254; 1768-3254
• DOI: 10.1016/j.ejmech.2023.115765

Targeted Protein Modification (TPM) is an umbrella term encompassing numerous tools and approaches that use bifunctional agents to induce a desired modification over the POI. The most well-known TPM mechanism is PROTAC-directed protein ubiquitination. PROTAC-based targeted degradation offers several advantages over conventional small-molecule inhibitors, has shifted the drug discovery paradigm, and is acquiring increasing interest as over ten PROTACs have entered clinical trials in the past few years. Targeting the protein of interest for proteasomal degradation by PROTACS was the pioneer of various toolboxes for selective protein degradation. Nowadays, the ever-increasing number of tools and strategies for modulating and modifying the POI has expanded far beyond protein degradation, which phosphorylation and de-phosphorylation of the protein of interest, targeted acetylation, and selective modification of protein O-GlcNAcylation are among them. These novel strategies have opened new avenues for achieving more precise outcomes while remaining feasible and minimizing side effects. This field, however, is still in its infancy and has a long way to precede widespread use and translation into clinical practice. Herein, we investigate the pros and cons of these novel strategies by exploring the latest advancements in this field. Ultimately, we briefly discuss the emerging potential applications of these innovations in cancer therapy, neurodegeneration, viral infections, and autoimmune and inflammatory diseases.
[Display omitted]
•TPM is an umbrella term that used to induce a desired modification over the POI.•The most well-known TPM mechanism is PROTAC-directed protein ubiquitination.•PROTAC-based targeted degradation offers several advantages over conventional small-molecule inhibitors.